The metabolic implications of long term cannabis use in patients with psychosis

被引:4
|
作者
Mushtaq, Farrah [1 ]
Mondelli, Valeria [1 ]
Pariante, Carmine M. [1 ]
机构
[1] Kings Coll London, Inst Psychiat, James Black Ctr,Div Psychol Med, Ctr Cellular Basis Behav,SPI Lab, London SE5 9NU, England
基金
英国医学研究理事会;
关键词
cannabis; psychosis; weight; metabolic syndrome;
D O I
10.1017/S1121189X00001317
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Aims - The aim of this paper is to summarise the effects of cannabis use on appetite and energy balance, and to subsequently investigate the possible implications this may have in patients with psychosis, in whom a high prevalence of cannabis use has been reported. Methods - A narrative review based on the recent literature regarding cannabis use in the general population and patients with psychosis. Results - The short-term abilities of cannabis to increase appetite and body weight, through actions on the endogenous endocannabinoid system, have been well characterised throughout the literature. The long term effects of cannabis use are however unclear and only a minority of studies have been conducted in the genera. population with overall conflicting results. In terms of the effects of cannabis in patients with psychosis, there has only been one study to date that has investigated this and interestingly found cannabis use to be associated with increased body weight and blood glucose levels, thus providing evidence that cannabis use may be an important contributing factor to the reduced life expectancy, as is Currently observed in this vulnerable patient group. Conclusions - It is clear from the literature that patients with psychosis are at a high risk of metabolic and cardiovascular disease in comparison to the general population. However the contribution of cannabis use to this risk is as of yet undetermined and further long term studies are need to confirm Current findings and evaluate hypothesised mechanisms.
引用
收藏
页码:221 / 226
页数:6
相关论文
共 50 条
  • [21] Cannabis use and psychosis onset
    Cretu, A.
    Garaz, G.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2012, 22 : S401 - S401
  • [22] Cannabis and First-Episode Psychosis: Different Long-term Outcomes Depending on Continued or Discontinued Use
    Gonzalez-Pinto, Ana
    Alberich, Susana
    Barbeito, Sara
    Gutierrez, Miguel
    Vega, Patricia
    Ibanez, Berta
    Haidar, Mahmoud Karim
    Vieta, Eduard
    Arango, Celso
    SCHIZOPHRENIA BULLETIN, 2011, 37 (03) : 631 - 639
  • [23] Long-term drug adherence in first-episode psychosis: the role of cannabis use and involuntary admission
    Martinez-Cengotitabengoa, M.
    Barbeito, S.
    Gonzalez-Ortega, I.
    Garcia-Alocen, A.
    Gonzalez-Pinto, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S496 - S497
  • [24] A comparison of symptoms and family history in schizophrenia with and without prior cannabis use: Implications for the concept of cannabis psychosis
    Boydell, J.
    Dean, K.
    Dutta, R.
    Giouroukou, E.
    Fearon, P.
    Murray, R.
    SCHIZOPHRENIA RESEARCH, 2007, 93 (1-3) : 203 - 210
  • [26] Delayed preattentional functioning in early psychosis patients with cannabis use
    Nicole Pesa
    Daniel F. Hermens
    Robert A. Battisti
    Manreena Kaur
    Ian B. Hickie
    Nadia Solowij
    Psychopharmacology, 2012, 222 : 507 - 518
  • [27] Cannabis use and involuntary admission may mediate long-term adherence in first-episode psychosis patients: a prospective longitudinal study
    Barbeito, Sara
    Vega, Patricia
    Ruiz de Azua, Sonia
    Saenz, Margarita
    Martinez-Cengotitabengoa, Monica
    Gonzalez-Ortega, Itxaso
    Bermudez, Cristina
    Hernanz, Margarita
    Fernandez de Corres, Blanca
    Gonzalez-Pinto, Ana
    BMC PSYCHIATRY, 2013, 13
  • [28] Delayed preattentional functioning in early psychosis patients with cannabis use
    Pesa, Nicole
    Hermens, Daniel F.
    Battisti, Robert A.
    Kaur, Manreena
    Hickie, Ian B.
    Solowij, Nadia
    PSYCHOPHARMACOLOGY, 2012, 222 (03) : 507 - 518
  • [29] Cannabis use increases body mass index in patients with psychosis
    Mondelli, V
    Di Forti, M
    Saeedzadeh-Sardahaee, F
    Butt, A
    Miorelli, A
    Mule, A
    Gafoor, R
    Dazzan, P
    Murray, RM
    Pariante, CM
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2006, 16 : S68 - S69
  • [30] Long-term outcome of clozapine use for psychosis among parkinsonian patients
    Fernandez, HH
    Donnelly, EM
    Friedman, JH
    MOVEMENT DISORDERS, 2002, 17 : S225 - S225